Group 1 - The major shareholder, Nanjing Qihe Venture Capital Partnership, held 25,798,000 shares of Shanghai Xuantai Pharmaceutical Technology Co., Ltd., accounting for 5.6907% of the total share capital before the reduction plan [1] - The reduction plan announced on July 15, 2025, indicated that the shareholder planned to reduce up to 4,500,000 shares through centralized bidding and up to 2,500,000 shares through block trading between August 5, 2025, and November 4, 2025 [1] - As of November 4, 2025, the shareholder reduced 3,218,000 shares through centralized bidding, representing 0.7098% of the current total share capital [2] Group 2 - The reduction plan was fully implemented as the actual reduction met the minimum reduction quantity disclosed earlier [3] - There were no early terminations of the reduction plan, confirming that the plan proceeded as scheduled [3]

Summary of Key Points Core Viewpoint - Several shareholders across various companies are planning to reduce their stakes, indicating potential shifts in ownership dynamics within the market [1]. Group 1: Shareholder Reductions - Hongbo New Materials' shareholder, Xinyu Baolong, intends to reduce its stake by 3% [1]. - Dayilong's shareholder, Lefeng Investment, has reduced its stake by 3% [1]. - Ningbo Zhongbai's Zhang Jiangbo plans to reduce his stake by 1% [1]. - Founder Securities reports that China Cinda plans to reduce its stake by 1% within three months [1]. - Liqun Co., Ltd.'s director, Hu Peifeng, intends to reduce his stake by 0.08% [1]. - Suli Co., Ltd.'s Guosheng Investment plans to reduce its stake by 0.4816% [1]. - Jinzhen Co., Ltd.'s Zhao Jian and Xu Minbo have reduced their stakes by 0.98% and 0.11%, respectively [1]. - Shenkong Technology's Wang Huan and Zhou Baocong plan to reduce their stakes by up to 0.0263% and 0.0210% within three months [1]. - Huaxi Biological's shareholder, Guoshou Chengda, plans to reduce its stake by no more than 2% [1]. - Xuanta Pharmaceutical's Qihe Venture has reduced its stake by 0.7098% [1]. - Desheng Technology's actual controller, Guo Xiaobin, has reduced his stake by 0.51% [1]. - Liren Technology's Liren Investment has reduced its stake by 0.0779% [1]. Group 2: Shareholder Increases - Zhongju Gaoxin's Li Ruxiong has increased his stake by 0.0129% [1].

证券代码：688247 证券简称：宣泰医药 公告编号：2025-047 上海宣泰医药科技股份有限公司 关于持股 5%以上股东减持计划时间届满暨 减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 一、减持主体减持前基本情况 | 股东名称 | 南京市栖和创业投资合伙企业（有限合伙） | | | | --- | --- | --- | --- | | 股东身份 | 控股股东、实控人及一致行动人 | □是 | √否 | | | 直接持股 5%以上股东 | √是 | □否 | | | 董事、监事和高级管理人员 | □是 | √否 | | | 其他：/ | | | | 持股数量 | 25,798,000股 | | | | 持股比例 | 5.6907% | | | | 当前持股股份来源 | IPO 前取得：25,798,000股 | | | 上述减持主体无一致行动人。 二、减持计划的实施结果 （一）大股东因以下事项披露减持计划实施结果： 大股东持股的基本情况 本次减持计划实施前，上海宣泰医药科 ...

证券代码：688247 证券简称：宣泰医药 公告编号：2025-048 上海宣泰医药科技股份有限公司 关于参加 2025 年上海辖区上市公司三季报 集体业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 会议召开时间：2025 年 11 月 13 日（星期四） 15:00-16:30 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 11 月 6 日（星期四）至 11 月 12 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过上海宣泰医药科技 股份有限公司（以下简称"公司"）邮箱 info@sinotph.com 进行提问。公司将在说 明会上对投资者普遍关注的问题进行回答。 公司已于 2025 年 10 月 31 日发布公司 2025 年第三季度报告，为便于广大投 资者更全面深入地了解公司 2025 ...

Core Viewpoint - Nanjing Qihe Venture Capital Partnership (Limited Partnership) has completed its share reduction plan for Xuantai Pharmaceutical, selling a total of 3.218 million shares, which represents a reduction of 0.7098% of its holdings [1] Summary by Sections - **Shareholding Details** - The shareholder originally held 25.798 million shares, accounting for 5.6907% of the total shares [1] - After the reduction, the current holding is 22.58 million shares, representing 4.9808% of the total shares [1] - **Reduction Plan** - The reduction plan was implemented from August 5, 2025, to November 4, 2025 [1] - The shares were sold through centralized bidding at a price range of 10.5 to 13.13 yuan per share [1] - The total cash generated from the sale was approximately 37.4141 million yuan [1]

Core Insights - The company reported a revenue of 331 million yuan and a net profit of 63.46 million yuan for the first three quarters of 2025, with a quarterly revenue of 112 million yuan and a net profit of 17.88 million yuan in Q3 [1] - The company is accelerating product commercialization and expanding its global market presence, with its product Olaparib tablets expected to be selected in the recent national centralized drug procurement [1] - The company received FDA approval for its product Tocilizumab sustained-release tablets in October, marking a significant milestone in its product portfolio [1] Product Development - The company made breakthroughs in the diabetes sector, with the approval of new specifications for Sitagliptin Metformin sustained-release tablets by the National Medical Products Administration in September [2] - The product Sitagliptin Metformin sustained-release tablets also received temporary approval from the FDA in October, enhancing the company's international presence in diabetes treatment [2] - The company has established a solid foundation for entering the U.S. market with two products receiving temporary FDA approval in the first half of the year [2] High-end Generic Drugs - The company follows a "first generic, high activity" strategy, achieving global first-generic breakthroughs for several products, including Posaconazole enteric-coated tablets and Macitentan tablets [3] - The company has also received approvals for high-activity formulations such as Olaparib tablets and Exemestane tablets, establishing market barriers [3] - The company's self-developed modified new drug project XT-0043 has shown excellent safety and efficacy in Phase II clinical trials [3] Future Outlook - The company plans to continue driving innovation and steadily advancing its international layout strategy, focusing on enhancing its high-end generic and modified new drug pipeline [3] - The company aims to improve its production quality system and service capabilities while strengthening international cooperation to commercialize more products globally [3]

Core Viewpoint - The company, Shanghai Xuantai Pharmaceutical Co., Ltd., has reported significant developments in its product approvals and market strategies, which are expected to enhance its competitive position and market share in both domestic and international markets [7][9]. Financial Data - The financial statements for the third quarter are unaudited, and the report period covers three months from the beginning to the end of the quarter [3][9]. - The company has not reported any non-recurring gains or losses that are significant enough to be classified differently from regular financial metrics [4][9]. Shareholder Information - As of the end of the reporting period, the company holds 4,336,109 shares in its repurchase account, representing 0.96% of the total share capital [5]. Product Approvals and Market Expansion - The company received approval from the National Medical Products Administration (NMPA) for a new specification of its product, Sitagliptin Metformin Sustained-Release Tablets 50/500mg, which is expected to better meet patient needs and enhance market competitiveness [7]. - The product, Tocilizumab Sustained-Release Tablets 11mg, has received formal approval from the U.S. Food and Drug Administration (FDA), while Sitagliptin Metformin Sustained-Release Tablets have received temporary approval from the FDA, indicating potential for expanded sales in the U.S. market [7]. - The company’s product, Olaparib Tablets, is set to be included in the 11th batch of national centralized drug procurement, which could lead to increased sales and market share if procurement contracts are signed and executed [7].

Core Viewpoint - The company has demonstrated significant progress in its high-end generic drug and CRO/CMO businesses, achieving substantial revenue growth and regulatory approvals for key products in both domestic and international markets [1][2][3] Financial Performance - For the first three quarters of 2025, the company reported a revenue of 331 million yuan and a net profit attributable to shareholders of 63.46 million yuan [1] - In Q3 2025, the company achieved a revenue of 112 million yuan and a net profit of 17.88 million yuan [1] - R&D expenses reached 17.19 million yuan in Q3, accounting for 15.36% of total revenue, reflecting the company's commitment to innovation [2] Product Development and Approvals - The company received approval for new specifications of its Sitagliptin Metformin Extended-Release Tablets from the National Medical Products Administration in September 2025, enhancing its product matrix in the diabetes sector [1] - In October 2025, the same product received tentative approval from the FDA, marking a significant milestone in the company's internationalization efforts [1] - The company’s Tofacitinib Citrate Extended-Release Tablets 11mg specification received formal approval from the FDA in October [2] - The company’s Olaparib Tablets are expected to be selected in the recent national drug centralized procurement, which will help expand sales and market share [2] R&D and Innovation Strategy - The company focuses on a "first-to-market" strategy in high-end generics, achieving multiple first-generic breakthroughs globally [2] - The company has developed three proprietary R&D technology platforms: "Poorly Soluble Drug Solubilization Technology," "Controlled Release Drug Formulation R&D Platform," and "Fixed-Dose Combination Formulation R&D Platform" [2] - The first self-developed modified new drug project, XT-0043, has shown excellent safety and efficacy in Phase II clinical trials [2] CRO/CMO Business Development - The company leverages its dual-platform in China and the U.S. and multiple GMP certifications to deepen collaborations with domestic and international innovative drug companies [3] - The company has advanced over 100 innovative drug formulation development projects and has established a stable CMO production service model for several successfully launched innovative drugs [3] Future Outlook - The company plans to continue its innovation-driven strategy and steadily advance its international layout, focusing on enhancing its high-end generic and modified new drug pipelines [3] - The controlling shareholder has committed not to reduce its stake in the company for two years starting from August 25, 2025, reflecting confidence in the company's long-term development [3]

Core Insights - The company reported a revenue of 331 million yuan and a net profit of 63.46 million yuan for the first nine months of 2025, with a quarterly revenue of 112 million yuan and a net profit of 17.88 million yuan in Q3 [1] Group 1: Product Development and Market Expansion - The company achieved significant progress in its internationalization strategy, with the FDA approving its 11 mg formulation of tofacitinib citrate in October [1] - The diabetes pipeline saw breakthroughs, with the approval of a new specification for sitagliptin and metformin extended-release tablets by the National Medical Products Administration (NMPA) in September, enhancing the product matrix [2] - The company’s products are now available in multiple countries, including China, the USA, Australia, Canada, and Southeast Asia, creating a diversified global sales structure [2] Group 2: Regulatory Approvals and Quality Certifications - The company’s solid dosage form workshop received GMP certification from the European Medicines Agency (EMA) in July, maintaining a "zero-defect" record in inspections by major global regulatory agencies [3] - The company was awarded the highest information disclosure rating of "A" by the Shanghai Stock Exchange for the 2024-2025 information disclosure evaluation, reflecting its commitment to investor relations and transparency [3] Group 3: Strategic Commitments - The controlling shareholder, Shanghai Lianhe Investment Co., Ltd., voluntarily committed not to reduce its shareholding for two years starting from August 25, 2025, indicating confidence in the company's long-term development strategy [3]

Core Insights - Xuantai Pharmaceutical (688247.SH) reported a revenue of 331 million yuan for the first three quarters of 2025, representing a year-on-year decline of 8.59% [1] - The company's net profit attributable to shareholders was 63.46 million yuan, down 31.45% year-on-year [1] - The non-recurring net profit was 53.88 million yuan, reflecting a year-on-year decrease of 36.64% [1] - Basic earnings per share stood at 0.14 yuan [1]